As action to the COVID-19 outbreak, we are assessing the potential difference RJx-01, our safe and well tolerated combination drug, can make.

Biology of aging

Major progress has been made in the biology of aging also known as geroscience. This has resulted in a better scientific understanding of the biological processes associated with age-related functional decline. Several mechanisms have been elucidated and drugable targets have been identified.


Prescription drug

We identify opportunities to impact the aging process by repositioning Rx products. Our portfolio currently contains 7 individual compounds, selected via our Pre-Clinical and Clinical AI platform focusing on safety and their efficacy potential. Based on the succesful preclinical data, we are preparing our lead candidate for a POC study, starting in 2021.


Lead compound RJx-01

Our lead candidate RJx-01, and first entry into market, is a combination product indicated to treat Sarcopenia (muscle failure). Sarcopenia is the progressive loss of skeletal muscle quality / mass and strength. It affects 2-24% of the overall population, and 50% of 80 year old. It increases the risk of physical disability, poor quality of life and death.


Latest news

Scientific Advisory Board meeting: review of preclinical data

In August, our scientific advisory board reviewed the totality of our data. We were very pleased to hear that they concluded that these data support not only sarcopenia, but create multiple options in other muscle related and non-muscle related disorders. Based on their feedback we adjusted our funding strategy to optimize the clinical trajectory.

Key research collaboration with Rafael de Cabo

Professor Dr. Rafael de Cabo from NIA`s Translational Gerontology Branch under a Cooperative Research & Development Agreement (CRADA) will be our collaborator in evaluating effects on the characteristics of aging, incl overall health, survival & resilience.